

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Duvelisib for treating relapsed follicular lymphoma after at least 2 systemic therapies ID1090

Provisional stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Verastem Oncology (Duvelisib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> African Caribbean Leukaemia Trust Anthony Nolan Black Health Agency Blood Cancer UK British Skin Foundation Cancer Black Care Cancer Equality Cancer52 DKMS Helen Rollason Cancer Charity Independent Cancer Patients Voice Leukaemia Cancer Society Leukaemia CARE Lymphoma Action Macmillan Cancer Support Maggie's Centres Marie Curie South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care WMUK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> Association of Cancer Physicians British Association of Dermatologists British Committee for Standards in Haematology British Dermatological Nursing Group British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics & Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> Accord Healthcare (bendamustine, doxorubicin, etoposide, mitoxantrone, prednisolone) Allergan (prednisolone) Aspen (chlorambucil) Bausch & Lomb UK (prednisolone) Baxter Healthcare (cyclophosphamide, mitoxantrone) Bayer (prednisolone) Bristol-Myers Squibb (etoposide) Celgene (lenalidomide) Concordia International (prednisolone)

Provisional stakeholder list for the technology appraisal of duvelisib for treating relapsed follicular lymphoma after at least 2 systemic therapies ID1090. Issue date: August 2020

© National Institute for Health and Care Excellence 2020. All rights reserved.

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Society for Haematology • Cancer Research UK • Primary Care Dermatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiography • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Airedale, Wharfedale and Craven CCG • NHS England • NHS West London CCG • Welsh Government 	<ul style="list-style-type: none"> • Dr. Reddy's Laboratories (bendamustine) • Hospira UK (mitoxantrone, vincristine) • Intrapharm Laboratories (prednisolone) • Janssen-Cilag (doxorubicin) • Logixx Pharma Solutions (prednisolone) • Medac GmbH (bendamustine, doxorubicin, etoposide) • Merck Sharpe & Dohme (interferon alfa) • Napp Pharmaceuticals (rituximab, bendamustine) • Pfizer (doxorubicin) • Roche Products (interferon alfa, obinutuzumab, rituximab) • Sandoz (rituximab, cyclophosphamide) • Seacross Pharmaceuticals (doxorubicin) • Teva UK (doxorubicin) • Wockhardt UK (prednisolone) • Zentiva (bendamustine, prednisolone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Epidermo-Epidemiology Society • Cochrane Haematological Malignancies Group • Cochrane Skin Group • Genomics England • Institute of Cancer Research • Leukaemia UK • Leuka • Leukaemia Busters • Lymphoma Research Trust • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

Provisional stakeholder list for the technology appraisal of duvelisib for treating relapsed follicular lymphoma after at least 2 systemic therapies ID1090. Issue date: August 2020

© National Institute for Health and Care Excellence 2020. All rights reserved.

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.